ZTS logo

Zoetis Inc. Stock Price

NYSE:ZTS Community·US$31.2b Market Cap
  • 5 Narratives written by author
  • 0 Comments on narratives written by author
  • 258 Fair Values set on narratives written by author

ZTS Share Price Performance

US$77.27
-70.97 (-47.88%)
US$92.92
Fair Value
US$77.27
-70.97 (-47.88%)
16.8% undervalued intrinsic discount
US$92.92
Fair Value
Price US$77.27
ValueInvestingSubstack US$92.92
AnalystConsensusTarget US$114.76
AnimalDoctorKwon US$86.83

ZTS Community Narratives

·
Fair Value US$92.92 16.8% undervalued intrinsic discount

Zoetis down -50% over the past year

10users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
·
Fair Value US$114.76 32.7% undervalued intrinsic discount

ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters

5users have liked this narrative
0users have commented on this narrative
94users have followed this narrative
·
Fair Value US$86.83 11.0% undervalued intrinsic discount

Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
US$92.92
16.8% undervalued intrinsic discount
Revenue
4.06% p.a.
Profit Margin
28.03%
Future PE
12.76x
Price in 2031
US$131
US$86.83
11.0% undervalued intrinsic discount
Revenue
3.9% p.a.
Profit Margin
28.03%
Future PE
12.01x
Price in 2031
US$122.4
US$80
3.4% undervalued intrinsic discount
Revenue
2.96% p.a.
Profit Margin
29.06%
Future PE
11.51x
Price in 2029
US$98.06
US$114.76
32.7% undervalued intrinsic discount
Revenue
3.88% p.a.
Profit Margin
28.98%
Future PE
16.12x
Price in 2029
US$140.68
US$160
51.7% undervalued intrinsic discount
Revenue
5.88% p.a.
Profit Margin
29.36%
Future PE
20.95x
Price in 2029
US$196.13

Trending Discussion

No trending discussion available.

Updated Narratives

ZTS logo

Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?

Fair Value: US$86.83 11.0% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ZTS logo

Zoetis down -50% over the past year

Fair Value: US$92.92 16.8% undervalued intrinsic discount
29 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ZTS logo

ZTS: Future Therapies And Legal Risks Will Shape Confidence Reset

Fair Value: US$80 3.4% undervalued intrinsic discount
10 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued established dividend payer.

1 Risk
5 Rewards

Zoetis Inc. Key Details

US$9.5b

Revenue

US$2.7b

Cost of Revenue

US$6.8b

Gross Profit

US$4.2b

Other Expenses

US$2.7b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
6.37
71.84%
28.03%
280.3%
View Full Analysis

About ZTS

Founded
2012
Employees
14500
CEO
Kristin Peck
WebsiteView website
www.zoetis.com

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Recent ZTS News & Updates

Recent updates

No updates